Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Strong investor syndicate backs clinical-stage Hepatitis B program while advancing pioneering gene-tuning platform January 12, 2025 08:00 PM Eastern Standard Time DURHAM, N.C. & SEATTLE–(BUSINESS WIRE)–Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion…